U.S. Markets close in 1 hr 43 mins

Check-Cap Ltd. (CHEK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3553-0.0097 (-2.66%)
As of 2:17PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3650
Open0.3700
Bid0.3515 x 1400
Ask0.3559 x 1000
Day's Range0.3400 - 0.3800
52 Week Range0.2430 - 2.3700
Volume1,855,133
Avg. Volume1,480,667
Market Cap16.428M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.6600
Earnings DateNov 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
  • Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
    PR Newswire

    Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the third quarter and nine months ended September 30, 2020 and corporate highlights.

  • Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
    PR Newswire

    Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the second quarter and six months ended June 30, 2020.

  • Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds
    PR Newswire

    Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into cancer, today announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share. The warrants being exercised were issued by Check-Cap on several dates from November 2017 through May 2020 and have exercise prices ranging from $15.00 to $0.80 per share.